

AMENDMENTS TO THE CLAIMS

Please cancel Claims 1-10 without prejudice and insert therefore new Claims 11-20. This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-10 (canceled)

11. (new) A method for the treatment or prevention of a disease associated with the deposition of β -amyloid in the brain of a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of a growth hormone secretagogue, or a pharmaceutically acceptable salt thereof, and a PDE4 inhibitor, or a pharmaceutically acceptable salt thereof.

12. (new) The method of Claim 11 wherein the disease is Alzheimer's disease.

13. (new) A method for the treatment, prevention or delaying the onset of dementia associated with Alzheimer's disease, cerebral amyloid angiopathy, multi-infarct dementia, dementia pugilistica or Down syndrome in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of a growth hormone secretagogue, or a pharmaceutically acceptable salt thereof, and a PDE4 inhibitor, or a pharmaceutically acceptable salt thereof.

13. (new) A method for the treatment, prevention or delaying the onset of mild cognitive impairment in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of a growth hormone secretagogue, or a pharmaceutically acceptable salt thereof, and a PDE4 inhibitor, or a pharmaceutically acceptable salt thereof.

15. (new) The method of Claim 14 wherein the patient possesses one or more additional risk factors for developing Alzheimer's disease selected from: a family history of the disease; a genetic predisposition to the disease; elevated serum cholesterol; adult-onset diabetes mellitus; lowered baseline hippocampal volume; elevated CSF levels of total tau; elevated CSF levels of phospho-tau; and lowered CSF levels of A β 42.


16. (new) The method of Claim 11 wherein the growth hormone secretagogue is N-[1(R)-[(1,2-dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-2-amino-2-methyl-propanamide, or a pharmaceutically acceptable salt thereof.

17. (new) The method of Claim 16 wherein the growth hormone secretagogue is the methanesulfonate salt of N-[1(R)-[(1,2-dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidin]-1'-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-2-amino-2-methyl-propanamide.

18. (new) The method of Claim 11 wherein the the PDE4 inhibitor is selected from: 6-[1-methyl-1-(methylsulfonyl)ethyl]-8-[3-[(E)-2-[3-methyl-1,2,4-oxadiazol-5-yl]-2-[4-(methylsulfonyl)phenyl]ethenyl]phenyl]quinoline; and N-cyclopropyl-1-[3-(1-oxido-3-pyridinylethynyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide; or a pharmaceutically acceptable salt thereof.

19. (new) The method of Claim 18 wherein the the PDE4 inhibitor is the benzenesulfonate salt of 6-[1-methyl-1-(methylsulfonyl)ethyl]-8-[3-[(E)-2-[3-methyl-1,2,4-oxadiazol-5-yl]-2-[4-(methylsulfonyl)phenyl]ethenyl]phenyl]quinoline or N-cyclopropyl-1-[3-(1-oxido-3-pyridinylethynyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide.

20. (new) A pharmaceutical composition comprising, in a pharmaceutically acceptable carrier, a compound of formula I or a pharmaceutically acceptable salt thereof,



and the compound N-cyclopropyl-1-[3-(1-oxido-3-pyridinylethynyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide, or a pharmaceutically acceptable salt thereof.